Hepatitis C virus genotypes circulating in patients with chronic hepatitis C in Thailand and their responses to combined PEG-IFN and RBV therapy

Different genotypes of hepatitis C virus (HCV) are circulating in different areas of the world. In Thailand, distribution of HCV genotypes has been investigated mostly in the central area while the information in other regions is limited. This study aimed to determine the HCV genotypes circulating i...

Full description

Saved in:
Bibliographic Details
Main Authors: Kumthip K., Chusri P., Pantip C., Thongsawat S., O'Brien A., Nelson K.E., Maneekarn N.
Format: Article
Language:English
Published: John Wiley and Sons Inc. 2014
Online Access:http://www.ncbi.nlm.nih.gov/pubmed/24777626
http://www.scopus.com/inward/record.url?eid=2-s2.0-84901801479&partnerID=40&md5=833fcbea90dfe05758cedd322c14199f
http://cmuir.cmu.ac.th/handle/6653943832/1719
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University
Language: English
id th-cmuir.6653943832-1719
record_format dspace
spelling th-cmuir.6653943832-17192014-08-30T01:59:59Z Hepatitis C virus genotypes circulating in patients with chronic hepatitis C in Thailand and their responses to combined PEG-IFN and RBV therapy Kumthip K. Chusri P. Pantip C. Thongsawat S. O'Brien A. Nelson K.E. Maneekarn N. Different genotypes of hepatitis C virus (HCV) are circulating in different areas of the world. In Thailand, distribution of HCV genotypes has been investigated mostly in the central area while the information in other regions is limited. This study aimed to determine the HCV genotypes circulating in chronic hepatitis C patients in Chiang Mai, Thailand and to investigate the response of different HCV genotypes to pegylated interferon (PEG-IFN) and ribavirin (RBV) treatment. Patients infected chronically with HCV were treated with PEG-IFN/RBV based on the standard regimens for each HCV genotype and followed up the patients until the end of treatment and 6 months afterward. Out of 158 patients, three major HCV genotypes and eight subtypes were identified. Genotype 3 was the most predominant at 54.5%, followed by genotypes 1 (31%) and 6 (14.5%). Among subtypes, 3a was the most prevalent subtype (45%), followed by 1b (18.4%), 1a and 6f (each at 12.6%), 3b (9.5%), and 6a, 6i, 6n (each at 0.63%). Patients with genotype 3 showed higher rate of responding to the treatment at 80.2% compared to genotypes 1 (73.5%) and 6f (65%). Additionally, patients with genotype 6f showed higher rate of relapsing (25%) compared to genotypes 1 and 3 (14.3% and 16.3%, respectively). In conclusion, this study reported multiple HCV genotypes circulated in Thai patients and the response of different HCV genotypes to PEG-IFN/RBV treatment. J. Med. Virol. 86:1360-1365, 2014. © 2014 Wiley Periodicals, Inc. 2014-08-30T01:59:59Z 2014-08-30T01:59:59Z 2014 Article 10969071 10.1002/jmv.23962 JMVID http://www.ncbi.nlm.nih.gov/pubmed/24777626 http://www.scopus.com/inward/record.url?eid=2-s2.0-84901801479&partnerID=40&md5=833fcbea90dfe05758cedd322c14199f http://cmuir.cmu.ac.th/handle/6653943832/1719 English John Wiley and Sons Inc.
institution Chiang Mai University
building Chiang Mai University Library
country Thailand
collection CMU Intellectual Repository
language English
description Different genotypes of hepatitis C virus (HCV) are circulating in different areas of the world. In Thailand, distribution of HCV genotypes has been investigated mostly in the central area while the information in other regions is limited. This study aimed to determine the HCV genotypes circulating in chronic hepatitis C patients in Chiang Mai, Thailand and to investigate the response of different HCV genotypes to pegylated interferon (PEG-IFN) and ribavirin (RBV) treatment. Patients infected chronically with HCV were treated with PEG-IFN/RBV based on the standard regimens for each HCV genotype and followed up the patients until the end of treatment and 6 months afterward. Out of 158 patients, three major HCV genotypes and eight subtypes were identified. Genotype 3 was the most predominant at 54.5%, followed by genotypes 1 (31%) and 6 (14.5%). Among subtypes, 3a was the most prevalent subtype (45%), followed by 1b (18.4%), 1a and 6f (each at 12.6%), 3b (9.5%), and 6a, 6i, 6n (each at 0.63%). Patients with genotype 3 showed higher rate of responding to the treatment at 80.2% compared to genotypes 1 (73.5%) and 6f (65%). Additionally, patients with genotype 6f showed higher rate of relapsing (25%) compared to genotypes 1 and 3 (14.3% and 16.3%, respectively). In conclusion, this study reported multiple HCV genotypes circulated in Thai patients and the response of different HCV genotypes to PEG-IFN/RBV treatment. J. Med. Virol. 86:1360-1365, 2014. © 2014 Wiley Periodicals, Inc.
format Article
author Kumthip K.
Chusri P.
Pantip C.
Thongsawat S.
O'Brien A.
Nelson K.E.
Maneekarn N.
spellingShingle Kumthip K.
Chusri P.
Pantip C.
Thongsawat S.
O'Brien A.
Nelson K.E.
Maneekarn N.
Hepatitis C virus genotypes circulating in patients with chronic hepatitis C in Thailand and their responses to combined PEG-IFN and RBV therapy
author_facet Kumthip K.
Chusri P.
Pantip C.
Thongsawat S.
O'Brien A.
Nelson K.E.
Maneekarn N.
author_sort Kumthip K.
title Hepatitis C virus genotypes circulating in patients with chronic hepatitis C in Thailand and their responses to combined PEG-IFN and RBV therapy
title_short Hepatitis C virus genotypes circulating in patients with chronic hepatitis C in Thailand and their responses to combined PEG-IFN and RBV therapy
title_full Hepatitis C virus genotypes circulating in patients with chronic hepatitis C in Thailand and their responses to combined PEG-IFN and RBV therapy
title_fullStr Hepatitis C virus genotypes circulating in patients with chronic hepatitis C in Thailand and their responses to combined PEG-IFN and RBV therapy
title_full_unstemmed Hepatitis C virus genotypes circulating in patients with chronic hepatitis C in Thailand and their responses to combined PEG-IFN and RBV therapy
title_sort hepatitis c virus genotypes circulating in patients with chronic hepatitis c in thailand and their responses to combined peg-ifn and rbv therapy
publisher John Wiley and Sons Inc.
publishDate 2014
url http://www.ncbi.nlm.nih.gov/pubmed/24777626
http://www.scopus.com/inward/record.url?eid=2-s2.0-84901801479&partnerID=40&md5=833fcbea90dfe05758cedd322c14199f
http://cmuir.cmu.ac.th/handle/6653943832/1719
_version_ 1681419722939170816